UNASSIGNED:中肾腺癌(MNAC)是一种非常罕见的肿瘤,起源于女性生殖道的中肾导管残留物。文献中只报道了少数病例,大部分发生在子宫颈,在子宫体和卵巢中极为罕见。据报道,MNAC很少出现在子宫体,但从未在卵巢中报道过。最近提出了中肾样腺癌来描述这些由子宫体和卵巢引起的肿瘤。由于这种疾病的稀缺性,关于临床特征知之甚少,病理诊断,预后,以及MNAC在女性生殖系统中的优化管理策略。我们报告了一系列从阴道产生的MNAC,子宫颈,子宫体,子房,还有输卵管,总结临床特点,病理诊断,治疗,和预后。我们回顾性分析了2010年1月至2020年1月来自我们研究所的所有女性生殖道MNAC。患者的临床细节和随访来自医院记录,扫描来自图片存档和通信系统。共纳入11例患者。症状发作的中位年龄为52岁。所有患者均接受全子宫切除术和双侧附件卵巢切除术,7/11(63.6%)患者进行了淋巴结清扫。2/11(18.2%)术前接受新辅助化疗,7/11(63.6%)术后接受辅助化疗。在11名患者中,只有1例患者接受了辅助放疗.一名患者在这项研究的终点死亡,9例(81.8%)患者存活,1例患者失访。平均随访时间为33.5个月。尽管对于这种罕见疾病的最佳治疗尚无共识,根治性手术被认为是局部病变的初始选择。鉴于恶性程度高,大多数接受辅助化疗的MNAC或中肾样腺癌患者在初次手术后接受了4~8个周期的卡铂/紫杉醇作为一线治疗,中位无进展生存期为12个月.这些患者复发性疾病的治疗包括吉西他滨,卡铂,和紫杉醇。辐射在疾病的治疗中非常有限。
UNASSIGNED: Mesonephric adenocarcinoma (MNAC) is a very rare tumor that originates from mesonephric duct remnants of the female genital tract. Only a few cases were reported in the literature, and most of them occurred in the cervix, extremely rare in the uterine body and ovary. MNAC was rarely reported to arise in the uterine corpus, but never was reported in the ovary. Mesonephric-like adenocarcinomas are recently suggested to describe these neoplasms arising from the uterine corpus and ovary. Due to the rareness of the disease, little is known regarding clinical characteristics, pathological diagnosis, prognosis, and optimal management strategy of MNAC in the female reproductive system. We report a series of MNACs arising from the vagina, cervix, uterine corpus, ovary, and fallopian tube, to summarize the clinical characteristics, pathological diagnosis, treatment, and prognosis.We retrospectively analyzed all MNACs in the female genital tract derived from our institute from January 2010 till January 2020. Patients\' clinical details and follow-up were obtained from hospital records and scans were obtained from picture archiving and communication system.A total of 11 patients were included. The median age of onset of symptoms was 52 years. All patients underwent total hysterectomy and bilateral salpingo-oophorectomy, and lymph node dissections were performed in 7/11 (63.6%) patients. Two/eleven (18.2%) received neoadjuvant chemotherapy before surgery and 7/11 (63.6%) received adjuvant chemotherapy after primary surgery. Of the 11 patients, only 1 patient received adjuvant radiation therapy. One patient died at the end point of this study, 9 patients (81.8%) survived and 1 patient was lost to follow-up. The mean follow-up duration was 33.5 months.Although there is no consensus for the optimal treatment of this rare disease, radical surgery is considered to be the initial choice for localized lesion. Given the high malignancy, the majority of MNAC or mesonephric-like adenocarcinoma patients who underwent adjuvant chemotherapy received 4 to 8 cycles of carboplatin/paclitaxel as a first-line treatment after primary surgery with a median progression-free survival of 12 months. Treatment for recurrent disease in these patients included gemcitabine, carboplatin, and paclitaxel. Radiation was very limited in the treatment of the disease.